$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
释倍灵有什么版本的?
2025-10-19 11:44:20
Check Details
释倍灵的适应症是什么?
2025-10-19 11:44:20
Check Details
释倍灵治疗效果
2025-10-19 11:44:20
Check Details
释倍灵治疗多发性骨髓瘤疗效好吗?
2025-10-19 11:44:20
Check Details
释倍灵多少钱呢?
2025-10-19 11:44:20
Check Details
新诊断多发性骨髓瘤的MYC状态与风险分层相关
2025-10-19 11:44:20
Check Details
口服RAF-MEK抑制剂CH5126766在携带RAS/RAF突变的多种肿瘤中的抗肿瘤活性研究
2025-10-19 11:44:20
Check Details
雷利米得是化疗药还是靶向药?
2025-10-19 11:44:20
Check Details
雷利米得用法用量
2025-10-19 11:44:20
Check Details
雷利米得功效和作用
2025-10-19 11:44:20
Check Details
雷利米得一瓶吃多久?
2025-10-19 11:44:20
Check Details
雷利米得服用注意事项
2025-10-19 11:44:20
Check Details
1
2
...
1064
1065
1066
1067
1068
1069
1070
...
4162
4163
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Zongertinib for HER2-Mutant NSCLC: First-Line ORR About 76%, Brain Metastases Controlled, Manage Diarrhea and Hepatotoxicity
2
Selpercatinib Traditional Approval for RET Fusion Solid Tumors: Weight-Based Adults, BSA-Based Pediatrics, Monitor Liver, BP, QT
3
Atezolizumab Plus mFOLFOX as Adjuvant Therapy for Stage III dMMR Colon Cancer: ATOMIC DFS HR 0.50
4
Tucatinib Plus Trastuzumab and Pertuzumab Maintenance in HER2-Positive Advanced Breast Cancer: HER2CLIMB-05 Median PFS 24.9 Months
5
Zenocutuzumab (Bizengri) for NRG1 Fusion Solid Tumors: HER2×HER3 Bispecific, 750mg Q2W, NSCLC/Pancreas/Cholangiocarcinoma
6
Pemigatinib for FGFR2 Cholangiocarcinoma and FGFR1 Hematologic Use: First-Line Data, 21-Day Dosing, Phosphate and Ocular Management
7
Dabrafenib (Tafinlar) Complete Guide: Indications, Dosing, Combination Therapy and Safety
8
Binimetinib plus Encorafenib for BRAF‑Mutant Melanoma
9
Adagrasib (Krazati) for KRAS G12C: NSCLC Dosing, Titration, and CRC Regulatory Update
10
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
11
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
12
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks